NeoplasmsARAISENCT07721246
Simulation-Based Patient Education to Address Radiotherapy-Related Anxiety in Cancer Patients (ARAISE)
A study testing Simulation-Based Patient Education in people with Neoplasms and Anxiety, run by University Medical Center Goettingen at 1 site in Germany.
Trial summary
For the majority of cancer patients, radiotherapy is a crucial component of their treatment process. However, many patients experience anxiety before or during radiotherapy. This anxiety may be related not only to the cancer diagnosis and its prognosis but also to unfamiliar aspects of the treatment process, the… Read more about this study
- Who is it for?
- Ages 18 years and older
- What is being tested?
- Simulation-Based Patient Education
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 144 participants
- Where
- 1 siteGermany
- Study dates
- Jan 2028to Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older
- Histologically or cytologically confirmed malignant tumor disease
- Stage I - III (UICC TNM classification)
- ECOG performance status ≤ 2
- Curative-intent external beam radiotherapy regimen with at least 5 fractions
- First course of radiotherapy
Show all 9Show fewer
- Able to independently operate the electronic data collection instrument
- Written informed consent after study information
- Sufficient German language proficiency to read and complete the study questionnaires independently and without translation assistance
Who cannot join
- Lack of capacity to provide informed consent
- Pregnancy or breastfeeding
- Stereotactic radiotherapy
- Emergency treatment indication
- Acute suicidality, acute psychosis, or other acute psychiatric disorder
- Initiation of or dose change in psychotropic medication within 4 weeks before baseline (T0)
- Cognitive impairment that precludes independent completion of the questionnaires
- Visual or auditory impairment that prevents perception of the on-screen or audio content despite available aids
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Stephan-Peter Landgraff, M.Ed. contact
Germany1 site
Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen
Göttingen, Lower Saxony, 37075
Stephan-Peter Landgraff, M.Ed., +49 5513964501, stephan.landgraff@medicalschool-berlin.de
Rami El Shafie, Prof. Dr. med., +49 5513964501, rami.elshafie@med.uni-goettingen.de
About this study
Official title: Addressing Radiotherapy Anxiety Through Immersive Simulation and Education: Effects of a Simulation-Based Patient Education Intervention on Psychosocial Burden in Cancer Patients Receiving Radiotherapy (ARAISE)
For the majority of cancer patients, radiotherapy is a crucial component of their treatment process. However, many patients experience anxiety before or during radiotherapy. This anxiety may be related not only to the cancer diagnosis and its prognosis but also to unfamiliar aspects of the treatment process, the equipment, and the treatment environment. General or non-specific feelings of anxiety may also become associated with the radiotherapy setting, even when patients are not able to identify a specific treatment-related concern. Uncertainty about what will happen during treatment sessions can further increase anxiety and may affect patients' overall well-being. The ARAISE project consists of two consecutive parts. In the first part, health care professionals from different disciplines and patient representatives take part in a Delphi consensus process to identify and prioritize the treatment-specific fears of patients receiving radiotherapy. The results of this first part are used to define the content of the education session that is tested in the second part. The second part is a randomized controlled study in patients receiving radiotherapy for cancer. Participants will be assigned by chance, in equal numbers, to one of two groups. All participants will receive the usual patient education provided before radiotherapy. In addition, participants in one group will receive a single immersive, simulation-based education session after the planning CT scan and before the start of treatment. The main question is whether the additional session leads to lower state anxiety at the first radiotherapy fraction compared with usual patient education alone. The study also compares state anxiety at other time points, health-related quality of life, and how well informed participants feel about their treatment. Finally, the study assesses whether the additional education session is feasible, well accepted, and practical to provide as part of routine radiotherapy care.
Read the detailed description
Despite continued medical progress, cancer remains one of the leading causes of death worldwide. A significant number of cancer patients receive radiation therapy at some point during the treatment process, depending on the expected therapeutic benefit. The continued rise in the incidence of malignant diseases highlights the need to refine existing treatment pathways and integrate them into a comprehensive continuum of patient-centered care. A key component of these efforts is the systematic collection and assessment of the needs of patients in a growing and increasingly diverse patient population. In the field of radiation therapy, anxiety and psychological distress are clinically relevant factors that may have a lasting negative impact both on the subjective treatment experience and on treatment compliance, treatment preparation, and treatment quality. A large percentage of radiation therapy patients experience a level of psychological distress that is considered clinically significant and requires treatment. The resulting needs can be categorized into physical, psychological, and social dimensions, and the extent of the observed psychological distress varies significantly among different tumor types but essentially remains stable over the treatment course, with a slight tendency to decrease. Assessments of patient needs often differ among the professional groups participating in the therapy process. The currently standard practice of information counseling conducted by a physician alone is often insufficient to effectively address or alleviate existing treatment-related anxieties. The state-trait anxiety model developed by Charles Spielberger distinguishes between two different forms of anxiety. State anxiety describes a temporary emotional state associated with increased stimulation of the autonomic nervous system, and its intensity can fluctuate. In the context of radiation therapy, potential triggers may include the treatment machine with its specific sounds, the windowless treatment room with its heavy lead-lined door, and the inevitable situation in which the patient is alone during the treatment session. Trait anxiety, on the other hand, is a dispositional factor that represents a stable personality trait and describes the tendency to mistakenly assess objectively low-risk situations as threatening and to react with a disproportionately high level of anxiety. Both dimensions are relevant to the study context, as patients with pronounced trait anxiety generally react more strongly to stress-inducing situations, which in turn can manifest as increased state anxiety. The State-Trait Anxiety Inventory (STAI) is the established tool for the standardized assessment of both dimensions. A validated German-language adaptation (STAI-G) is available. To address these fears, immersive simulation techniques that provide patient-oriented guidance and, as a result, offer more personalized, one-on-one counseling can be valuable in alleviating the anxiety. The ARAISE project addresses these gaps in two consecutive parts. The first study part is a Delphi consensus procedure comprising two to three rounds involving radiation therapists, psycho-oncologists, patient representatives, physicians, and users of the VERT simulation software. In this process, treatment-specific fears of patients undergoing radiation therapy are identified from a multiprofessional perspective and ranked by priority. Its results determine the content of the educational intervention evaluated in the second study part. The subsequent second study part is a prospective, single-center, randomized controlled study with a 1-to-1 allocation ratio and a planned sample size of 144 patients. The participants in the control group receive standard counseling, provided prior to the start of radiation therapy. Participants in the intervention group will receive the same standard counseling, supplemented by a one-time, structured, simulation-based counseling session lasting 15 to 20 minutes, which will be conducted after the planning CT scan and before the first radiation therapy fraction. The session uses the immersive radiation therapy simulation software VERT 9.0 and is led by the principal investigator conducting the study, a medical educator with many years of clinical experience in radiation therapy. Assessments are performed at four time points: T0 (baseline before randomization), T1 (immediately after the planning CT or after the education session), T2 (first radiotherapy fraction), and T3 (fifth radiotherapy fraction). The primary endpoint is state anxiety at T2, measured with the STAI-G Form X1 and adjusted for the baseline value at T0. Secondary endpoints are state anxiety at T1 and T3, HRQoL at T3 (EORTC QLQ-C30), and the perceived amount of information received at T1 (EORTC QLQ-INFO25). Overall, ARAISE aims to develop and evaluate a patient-centered educational approach that may improve patients' preparation for radiotherapy and support the integration of their individual informational and psychological needs into routine care.
- Being tested
- Simulation-Based Patient Education
- Keywords
- Radiotherapy, State-Trait Anxiety Inventory, Patient Education, Simulation Training, Quality of Life, VERT, Psycho-Oncology
- Medical subject headings
- Neoplasms, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Simulation-Based Patient EducationOther
A single, standardized, simulation-based patient education session lasting 15 to 20 minutes, conducted in addition to the standard education session that takes place after the planning CT scan and before the first radiation therapy fraction. This session uses the immersive radiation therapy simulation software VERT 9.0 to visualize the treatment room, the linear accelerator, and the treatment process. In addition to illustrating the treatment process, targeted information is provided to address treatment-specific fears identified as priorities in the Delphi consensus. The session is conducted by the principal investigator following a standardized procedure to ensure comparability among participants. The prescribed oncological treatment and routine radiation therapy remain unchanged.
| Study group | Role | What they receive |
|---|---|---|
| Standard Patient Education | No intervention | Participants receive standard patient education before radiotherapy according to routine clinical practice. Standard patient education comprises the physician consultation covering the indication and aim of radiotherapy, treatment planning and delivery, possible acute and late side effects, and organizational aspects of care. No simulation-based education session is provided. Prescribed oncological treatment and routine radiotherapy care are not altered. |
| Simulation-Based Patient Education | Experimental | Participants receive standard patient education as in the control arm and, in addition, a single structured simulation-based patient education session after the planning CT and before the first radiotherapy fraction. Receives: Other: Simulation-Based Patient Education |
What is being measured
The primary outcome is the main question the study is designed to answer.
State anxiety at the first radiotherapy fraction (STAI-G Form X1)
State anxiety at the first radiotherapy fraction (T2), measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G). The sum score comprises 20 items and ranges from 20 to 80, with higher scores indicating greater state anxiety. The adjusted between-group difference in means at T2 is analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor. The effect measure is the adjusted mean difference with a 95% confidence interval.
Measured: First radiotherapy fraction (T2), approximately 2 weeks after randomization
Secondary outcomes (5)
State anxiety after the planning CT or education session (STAI-G Form X1)
State anxiety at T1, measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G). Scores range from 20 to 80, with higher scores indicating greater state anxiety. Analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor.
Measured: T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
State anxiety at the fifth radiotherapy fraction (STAI-G Form X1)
State anxiety at T3, measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G). Scores range from 20 to 80, with higher scores indicating greater state anxiety. Analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor.
Measured: Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
Health-related quality of life: Global Health Status/Quality of Life (EORTC QLQ-C30)
Health-related quality of life at T3, measured with the EORTC QLQ-C30 and linearly transformed to a score from 0 to 100, with higher scores indicating a greater global health status and quality of life. Analyzed by analysis of covariance with group as a factor, the T0 Global Health Status/Quality of Life score as a continuous covariate, and dichotomized trait anxiety at T0 as a factor. Functioning and symptom scales are reported descriptively only.
Measured: Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
Perceived amount of information received: "Information about the treatment" scale (EORTC QLQ-INFO25)
Perceived amount of information received at T1, measured with the multi-item scale "Information about the treatment" (items 38 to 43) of the EORTC QLQ-INFO25 and linearly transformed to a score from 0 to 100, with higher scores indicating a greater perceived amount of information. Groups are compared in a linear model with group as a factor and dichotomized trait anxiety at T0 as the only adjustment variable. The remaining multi-item scales, single items, the total score, and the assessment at T2 are reported descriptively.
Measured: T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
Feasibility of the simulation-based patient education intervention
Composite descriptive endpoint with target values defined a priori: recruitment rate of at least 50%, retention rate of at least 80% at T3, protocol adherence of at least 90%, data completeness of at least 85% from T0 to T3, and tolerability defined as discontinuation due to intervention-associated distress reactions in no more than 10% of participants. All rates are reported with two-sided 95% confidence intervals. No formal hypothesis testing is performed.
Measured: From enrollment to the fifth radiotherapy fraction (T3), approximately 3 weeks per participant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2026
- Study startJan 2028 (estimated)
- Primary completionMay 2030 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, single-center, open-label, two-arm, parallel-group, randomized controlled proof-of-concept study. Participants are randomly assigned 1:1 to standard patient education alone or to standard patient education plus a single simulation-based education session delivered after the planning CT and before the first radiotherapy fraction. Randomization is stratified by dichotomized trait anxiety. A preceding non-interventional Delphi consensus process informs the content of the intervention.
- Masking
- None (open label)
- Enrolment
- 144 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Medical Center Goettingen
- Sponsor type
- University, hospital or other
- Collaborators
- Medical School Berlin
- Responsible party
- Principal investigator, Prof. Dr. Rami El Shafie, University Medical Center Goettingen
- Investigators
- Rami El Shafie, Prof. Dr. med., Principal investigator, Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen (UMCG)Stephan-Peter Landgraff, M.Ed., Study director, Faculty of Health Sciences, Medical School Berlin (MSB)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07721246
- Sponsor's protocol ID
- ARAISE-RT-UMG-2026
- Acronym
- ARAISE
- Status last verified
- Aug 2026
- First submitted
- 17 Jul 2026
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared with external researchers. Study data contain sensitive health information and will be stored and analyzed in pseudonymized form on secure institutional servers in accordance with the study protocol and applicable data-protection requirements.
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Addressing Radiotherapy Anxiety Through Immersive Simulation and Education: Effects of a Simulation-Based Patient Education Intervention on Psychosocial Burden in Cancer Patients Receiving Radiotherapy (ARAISE)
- ClinicalTrials.gov ID
- NCT07721246
- Acronym / sponsor ID
- ARAISE / ARAISE-RT-UMG-2026
- Keywords
- Radiotherapy, State-Trait Anxiety Inventory, Patient Education, Simulation Training, Quality of Life, VERT, Psycho-Oncology
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 144 participants (estimated)
- Lead sponsor
- University Medical Center GoettingenUniversity, hospital or other
- Collaborators
- Medical School Berlin
- Study start
- Jan 2028 (estimated)
- Primary completion
- May 2030 (estimated)
- Study completion
- Dec 2030 (estimated)
- First posted
- 23 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
For the majority of cancer patients, radiotherapy is a crucial component of their treatment process. However, many patients experience anxiety before or during radiotherapy. This anxiety may be related not only to the cancer diagnosis and its prognosis but also to unfamiliar aspects of the treatment process, the equipment, and the treatment environment. General or non-specific feelings of anxiety may also become associated with the radiotherapy setting, even when patients are not able to identify a specific treatment-related concern. Uncertainty about what will happen during treatment sessions can further increase anxiety and may affect patients' overall well-being. The ARAISE project consists of two consecutive parts. In the first part, health care professionals from different disciplines and patient representatives take part in a Delphi consensus process to identify and prioritize the treatment-specific fears of patients receiving radiotherapy. The results of this first part are used to define the content of the education session that is tested in the second part. The second part is a randomized controlled study in patients receiving radiotherapy for cancer. Participants will be assigned by chance, in equal numbers, to one of two groups. All participants will receive the usual patient education provided before radiotherapy. In addition, participants in one group will receive a single immersive, simulation-based education session after the planning CT scan and before the start of treatment. The main question is whether the additional session leads to lower state anxiety at the first radiotherapy fraction compared with usual patient education alone. The study also compares state anxiety at other time points, health-related quality of life, and how well informed participants feel about their treatment. Finally, the study assesses whether the additional education session is feasible, well accepted, and practical to provide as part of routine radiotherapy care.
Detailed description
Despite continued medical progress, cancer remains one of the leading causes of death worldwide. A significant number of cancer patients receive radiation therapy at some point during the treatment process, depending on the expected therapeutic benefit. The continued rise in the incidence of malignant diseases highlights the need to refine existing treatment pathways and integrate them into a comprehensive continuum of patient-centered care. A key component of these efforts is the systematic collection and assessment of the needs of patients in a growing and increasingly diverse patient population. In the field of radiation therapy, anxiety and psychological distress are clinically relevant factors that may have a lasting negative impact both on the subjective treatment experience and on treatment compliance, treatment preparation, and treatment quality. A large percentage of radiation therapy patients experience a level of psychological distress that is considered clinically significant and requires treatment. The resulting needs can be categorized into physical, psychological, and social dimensions, and the extent of the observed psychological distress varies significantly among different tumor types but essentially remains stable over the treatment course, with a slight tendency to decrease. Assessments of patient needs often differ among the professional groups participating in the therapy process. The currently standard practice of information counseling conducted by a physician alone is often insufficient to effectively address or alleviate existing treatment-related anxieties. The state-trait anxiety model developed by Charles Spielberger distinguishes between two different forms of anxiety. State anxiety describes a temporary emotional state associated with increased stimulation of the autonomic nervous system, and its intensity can fluctuate. In the context of radiation therapy, potential triggers may include the treatment machine with its specific sounds, the windowless treatment room with its heavy lead-lined door, and the inevitable situation in which the patient is alone during the treatment session. Trait anxiety, on the other hand, is a dispositional factor that represents a stable personality trait and describes the tendency to mistakenly assess objectively low-risk situations as threatening and to react with a disproportionately high level of anxiety. Both dimensions are relevant to the study context, as patients with pronounced trait anxiety generally react more strongly to stress-inducing situations, which in turn can manifest as increased state anxiety. The State-Trait Anxiety Inventory (STAI) is the established tool for the standardized assessment of both dimensions. A validated German-language adaptation (STAI-G) is available. To address these fears, immersive simulation techniques that provide patient-oriented guidance and, as a result, offer more personalized, one-on-one counseling can be valuable in alleviating the anxiety. The ARAISE project addresses these gaps in two consecutive parts. The first study part is a Delphi consensus procedure comprising two to three rounds involving radiation therapists, psycho-oncologists, patient representatives, physicians, and users of the VERT simulation software. In this process, treatment-specific fears of patients undergoing radiation therapy are identified from a multiprofessional perspective and ranked by priority. Its results determine the content of the educational intervention evaluated in the second study part. The subsequent second study part is a prospective, single-center, randomized controlled study with a 1-to-1 allocation ratio and a planned sample size of 144 patients. The participants in the control group receive standard counseling, provided prior to the start of radiation therapy. Participants in the intervention group will receive the same standard counseling, supplemented by a one-time, structured, simulation-based counseling session lasting 15 to 20 minutes, which will be conducted after the planning CT scan and before the first radiation therapy fraction. The session uses the immersive radiation therapy simulation software VERT 9.0 and is led by the principal investigator conducting the study, a medical educator with many years of clinical experience in radiation therapy. Assessments are performed at four time points: T0 (baseline before randomization), T1 (immediately after the planning CT or after the education session), T2 (first radiotherapy fraction), and T3 (fifth radiotherapy fraction). The primary endpoint is state anxiety at T2, measured with the STAI-G Form X1 and adjusted for the baseline value at T0. Secondary endpoints are state anxiety at T1 and T3, HRQoL at T3 (EORTC QLQ-C30), and the perceived amount of information received at T1 (EORTC QLQ-INFO25). Overall, ARAISE aims to develop and evaluate a patient-centered educational approach that may improve patients' preparation for radiotherapy and support the integration of their individual informational and psychological needs into routine care.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Prospective, single-center, open-label, two-arm, parallel-group, randomized controlled proof-of-concept study. Participants are randomly assigned 1:1 to standard patient education alone or to standard patient education plus a single simulation-based education session delivered after the planning CT and before the first radiotherapy fraction. Randomization is stratified by dichotomized trait anxiety. A preceding non-interventional Delphi consensus process informs the content of the intervention.
| Arm | Type | Receives |
|---|---|---|
| Standard Patient Education | No intervention | –Participants receive standard patient education before radiotherapy according to routine clinical practice. Standard patient education comprises the physician consultation covering the indication and aim of radiotherapy, treatment planning and delivery, possible acute and late side effects, and organizational aspects of care. No simulation-based education session is provided. Prescribed oncological treatment and routine radiotherapy care are not altered. |
| Simulation-Based Patient Education | Experimental | Other: Simulation-Based Patient EducationParticipants receive standard patient education as in the control arm and, in addition, a single structured simulation-based patient education session after the planning CT and before the first radiotherapy fraction. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age 18 years or older
- Histologically or cytologically confirmed malignant tumor disease
- Stage I - III (UICC TNM classification)
- ECOG performance status ≤ 2
- Curative-intent external beam radiotherapy regimen with at least 5 fractions
Key exclusion criteria (8 listed)
- Lack of capacity to provide informed consent
- Pregnancy or breastfeeding
- Stereotactic radiotherapy
- Emergency treatment indication
- Acute suicidality, acute psychosis, or other acute psychiatric disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Simulation-Based Patient EducationA single, standardized, simulation-based patient education session lasting 15 to 20 minutes, conducted in addition to the standard education session that takes place after the planning CT scan and before the first radiation therapy fraction. This session uses the immersive radiation therapy simulation software VERT 9.0 to visualize the treatment room, the linear accelerator, and the treatment process. In addition to illustrating the treatment process, targeted information is provided to address treatment-specific fears identified as priorities in the Delphi consensus. The session is conducted by the principal investigator following a standardized procedure to ensure comparability among participants. The prescribed oncological treatment and routine radiation therapy remain unchanged. | Other | Simulation-Based Patient Education |
Primary outcome
State anxiety at the first radiotherapy fraction (STAI-G Form X1)
Time frame: First radiotherapy fraction (T2), approximately 2 weeks after randomization
State anxiety at the first radiotherapy fraction (T2), measured with the state scale (Form X1) of the German version of the State-Trait Anxiety Inventory (STAI-G). The sum score comprises 20 items and ranges from 20 to 80, with higher scores indicating greater state anxiety. The adjusted between-group difference in means at T2 is analyzed by analysis of covariance with the baseline state anxiety score at T0 as a continuous covariate and dichotomized trait anxiety at T0 as a factor. The effect measure is the adjusted mean difference with a 95% confidence interval.
5 secondary outcomes
State anxiety after the planning CT or education session (STAI-G Form X1)
Time frame: T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
State anxiety at the fifth radiotherapy fraction (STAI-G Form X1)
Time frame: Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
Health-related quality of life: Global Health Status/Quality of Life (EORTC QLQ-C30)
Time frame: Fifth radiotherapy fraction (T3), approximately 3 weeks after randomization
Perceived amount of information received: "Information about the treatment" scale (EORTC QLQ-INFO25)
Time frame: T1, immediately after the planning CT or after the education session, approximately 1 week after randomization
Feasibility of the simulation-based patient education intervention
Time frame: From enrollment to the fifth radiotherapy fraction (T3), approximately 3 weeks per participant
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared with external researchers. Study data contain sensitive health information and will be stored and analyzed in pseudonymized form on secure institutional servers in accordance with the study protocol and applicable data-protection requirements.
Related trials for Neoplasms
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stephan-Peter Landgraff, M.Ed. contact
Rami El Shafie, Prof. Dr. med. principal investigator
Department of Radiotherapy and Radiation Oncology, University Medical Center Goettingen (UMCG)
Stephan-Peter Landgraff, M.Ed. study director
Faculty of Health Sciences, Medical School Berlin (MSB)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Simulation-Based Patient Education in people with Neoplasms and Anxiety, run by University Medical Center Goettingen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Stephan-Peter Landgraff, M.Ed. (+49 30 76 68 37 5 600, stephan.landgraff@medicalschool-berlin.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
State anxiety at the first radiotherapy fraction (STAI-G Form X1) (time frame: First radiotherapy fraction (T2), approximately 2 weeks after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026.